$NTRA

Chapman Steven Leonard sold $1.2M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 5,499 shares of Natera, Inc. (NTRA) at $216.13 ($1.19M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not, by itself, indicate a change in company fundamentals.

02

Market read

This is a disclosed insider sale; any trading impact is likely limited and sentiment-driven rather than catalyst-driven.

03

What to watch

Traders may overreact to insider sales; the key mitigating factor is the explicitly pre-arranged 10b5-1 plan, which often correlates with routine scheduled selling.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5 for a June 4 sale

Background

The filing is an SEC Form 4 insider transaction disclosure for Natera (NTRA), reported as an open-market sale by the CEO/president under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and president Chapman Steven Leonard sold $1.19M of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Near-term impact likely muted; any reaction may be short-lived unless accompanied by other negative catalysts.

Evidence & confidence

Form 4 provides a concrete datapoint (sale size/price/date) but explicitly indicates a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity without sector-wide catalyst.

None.

None.

Counterpoint

Even with 10b5-1, the sale size could still reflect personal liquidity needs rather than bearish expectations; price may ignore it.

Key entities

  • Natera, Inc.

    Company whose shares were sold by its CEO/president under a 10b5-1 plan.

  • Chapman Steven Leonard

    CEO and president who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.